Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Enterprise Value: 2020-2025

Historic Enterprise Value for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to $2.9 billion.

  • GeneDx Holdings' Enterprise Value rose 186.34% to $2.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 270.13%. This contributed to the annual value of $2.0 billion for FY2024, which is 3441.35% up from last year.
  • Per GeneDx Holdings' latest filing, its Enterprise Value stood at $2.9 billion for Q3 2025, which was up 17.63% from $2.5 billion recorded in Q2 2025.
  • Over the past 5 years, GeneDx Holdings' Enterprise Value peaked at $3.5 billion during Q1 2021, and registered a low of -$59.0 million during Q4 2023.
  • Over the past 3 years, GeneDx Holdings' median Enterprise Value value was $576.5 million (recorded in 2024), while the average stood at $1.0 billion.
  • Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 169.30% in 2023, then surged by 13,882.23% in 2024.
  • Quarterly analysis of 5 years shows GeneDx Holdings' Enterprise Value stood at $675.5 million in 2021, then tumbled by 103.24% to -$21.9 million in 2022, then slumped by 169.30% to -$59.0 million in 2023, then spiked by 3,441.35% to $2.0 billion in 2024, then soared by 186.34% to $2.9 billion in 2025.
  • Its last three reported values are $2.9 billion in Q3 2025, $2.5 billion for Q2 2025, and $2.3 billion during Q1 2025.